Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Genitourinary 3Gastrointestinal 3Dermatologic 3Thoracic 2Sarcoma 2Lymphoid 2Head & Neck 2CNS 2Breast 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Wilms Tumor 7Neuroblastoma 7Hepatoblastoma 7Glioma 7Rhabdoid Tumor 6Osteosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Multiple Myeloma 6Medulloblastoma 6Lymphoma 6Leukemia, Myeloid, Acute 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma 5Rhabdomyosarcoma 5Lymphoma, Large B-Cell, Diffuse 5Central Nervous System Neoplasms 5Sarcoma, Ewing 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Burkitt Lymphoma 4Lymphoma, T-Cell 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Mycosis Fungoides 2Melanoma 2

Interventions

pembrolizumab 3copanlisib 2aflibercept 2X-Rays 2Specimen Handling 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1selinexor 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1epacadostat 1enzalutamide 1entinostat 1defactinib 1dabrafenib 1ciforadenant 1capivasertib 1binimetinib 1atezolizumab 1adavosertib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × X-Rays × Lymphoid × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡